Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
This article was originally published in The Pink Sheet Daily
Executive Summary
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.
You may also be interested in...
Ranbaxy’s First Biosimilar Target Will Be Amgen’s Neupogen
Ranbaxy is partnered with another Indian drug maker, Zenotech, in its foray into biosimilar development.
HHS’ Azar Departing To Explore Private Sector Opportunities
Deputy Sectary to leave after five and a half years with department; no successor announced.
Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.